Gregory M. Vercellotti
Affiliations: | Microbiology, Immunology and Cancer Biology | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Medicine and Surgery, Molecular Biology, Animal Physiology BiologyGoogle:
"Gregory Vercellotti"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Beckman JD, Zhang P, Nguyen J, et al. (2024) Missing the mark(ers): circulating endothelial cells and endothelial-derived extracellular vesicles are elevated in sickle cell disease plasma. Frontiers in Immunology. 15: 1493904 |
| Ivy ZK, Belcher JD, Khasabova IA, et al. (2023) Cold exposure induces vaso-occlusion and pain in sickle mice that depend on complement activation. Blood |
| Belcher JD, Nataraja S, Abdulla F, et al. (2023) The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell disease. Frontiers in Medicine. 10: 1101501 |
| Beckman JD, DaSilva A, Aronovich E, et al. (2023) JAK-STAT inhibition reduces endothelial pro-thrombotic activation and leukocyte- endothelial pro-adhesive interactions. Journal of Thrombosis and Haemostasis : Jth |
| Sparkenbaugh EM, Henderson MW, Miller-Awe MD, et al. (2023) Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. Blood |
| An R, Man Y, Cheng K, et al. (2023) Sickle red blood cell-derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factor. British Journal of Haematology |
| Belcher JD, Nguyen J, Chen C, et al. (2022) MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Translational Research : the Journal of Laboratory and Clinical Medicine |
| Gentinetta T, Belcher JD, Brügger-Verdon V, et al. (2022) Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine. 11 |
| El Jurdi N, Elhusseini H, Beckman J, et al. (2021) High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer Journal. 11: 96 |
| Zhang P, Nguyen J, Abdulla F, et al. (2021) Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells. Frontiers in Immunology. 12: 632709 |